Madrigal Pharma (MDGL) Misses Q3 EPS by 311c

Madrigal Pharma (NASDAQ: MDGL) reported Q3 EPS of ($5.08), $3.11 worse than the analyst estimate of ($1.97). Revenue for the quarter came in at $287.27 million versus the consensus estimate of $244.42 million.

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.

You May Also Be Interested In

• Anthropic Expected to Tell Investors It Sees a More Than $30T Total Addressable Market - WSJ
• The Marzetti Company (MZTI) Tops Q2 EPS by 6c
• Morgan Stanley Downgrades Nichirei Corp (2871:JP) to Equalweight